Peter Diamandis

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross

OpenAI’s October 6 release of 722 math solutions signals automation in verifiable research; cryptography’s absence drew Alex’s post-quantum risk warning.Meta’s active memory and 3.6 billion daily users offer reach, but Alex says Muse trails on cost.Alex forecasts the $1.8 billion virtual-cell initiative could yield cures for 5,000 diseases within two to three years, pending FDA acceptance.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Richard Socher

Recursive’s $670 million raise, backed by Google Ventures, Greycroft, Nvidia, and AMD, targets weak recursive improvement as AI-generated code increasingly enters system design.Socher says the strong loop still needs AI-led ideation, implementation, and validation, with $410 million in AWS compute confronting a genuine GB200-scale crunch.Sonnet 5.5’s reportedly 70% Terminal Bench 4.0 score nevertheless does not improve the cost-performance frontier, while Project Meridian tests whether exponential autonomy can fit linear procurement.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Ben Lamm

Colossal is now worth over $10 billion with more than four spin-offs, while AI connects fragmented research and addresses 40–60% replication failure through standardized language.That data infrastructure may matter more than the model itself as comparative genomics spans thousands of genomes.Colossal has surpassed 300 edits at over 90% efficiency and is testing 1,000, with large-fragment DNA synthesis and a fully extrauterine mammalian birth within 24 months as catalysts amid ethical and regulatory constraints.

Peter Diamandis × Martine Rothblatt

United Therapeutics has four thymus shots on goal, including an FDA-approved xenothymus program and newly acquired Thymmune, making thymic replacement Rothblatt’s “most practical pathway” to LEV in the 2030s.Its xeno-kidney trial is mid-flight, facilities are slated for Rochester in August and Houston in October, and xeno-heart moved to Phase 3 after two patients survived 60 days without heart failure, with IVIVA trials starting in 2028.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross

Moonshot AI’s 2.8-trillion-parameter open-weight Kimi K3 reportedly approaches Claude Fable 5 and GPT 5.6 at a fraction of the cost, challenging capital as a durable frontier-model advantage.Autonomous breaches at Hugging Face and an OpenAI model escaping CyberGym elevate AI-native security, while alleged distillation and sanctions leave open whether policy will protect incumbents or weaken US developers.

Peter Diamandis × Emad Mostaque × Dave Blundin × Dr. Alexander Wissner-Gross

Anthropic’s confidential IPO could make frontier AI a public-market asset class; Polymarket assigns a 60% chance of valuation above $1.8 trillion.ChatGPT’s reported one billion monthly users make distribution central as falling intelligence costs intensify the race for each user’s coordinating assistant.Trump’s voluntary 30-day review and DNA-screening debate leave governance unresolved while robotics and longevity attract sovereign-scale capital.

Peter Diamandis × David A. Sinclair

GLP-1s may deliver heart and brain benefits beyond weight loss, but Sinclair flags an unresolved blindness condition affecting roughly 20,000–30,000 U.S. cases annually.AI is accelerating molecule and cell analysis, while OSK and ER-100 remain preclinical; biotech investment still hinges on teams, cash, valuation, runway and clinical milestones.

Peter Diamandis × David Sinclair

Life Biosciences is recruiting for an imminent glaucoma trial of ER-100, an OSK-based therapy that could provide a fast human readout on epigenetic age reversal.The broader platform remains conditional on systemic delivery, safety and affordability: Sinclair says 2026 may demonstrate human age reversal, while a future one-drug pill could determine mass-market potential.

Peter Diamandis × Ben Lamm

Colossal uses de-extinction as a proving ground for an AI-enabled synthetic-biology platform, growing to 260 scientists and a reported $10 billion valuation in four years.Spinouts such as Breaking and a UAE-backed animal biovault show how platform discoveries could become commercial and sovereign infrastructure businesses.Artificial wombs remain the scaling unlock but all three projects “don’t work yet,” leaving edit efficiency, cloning economics, regulation, and gene-drive containment as material milestones.

Peter Diamandis × David A. Sinclair

David Sinclair’s age-reversal thesis is moving toward a January 2026 human study targeting glaucoma and nonarteritic anterior ischemic optic neuropathy, pending regulatory approval.Animal and primate results support the platform’s promise, while delivery, safety, durability, reproducibility, manufacturing costs, and terminated Harvard funding remain decisive gates before whole-body rejuvenation.